magnolol has been researched along with sirolimus in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Dong, G; Liu, N; Sheng, C; Wang, Y; Wu, S | 1 |
| Jia, J; Wang, X | 1 |
1 review(s) available for magnolol and sirolimus
| Article | Year |
|---|---|
Tackling Fungal Resistance by Biofilm Inhibitors.
Topics: Animals; Antifungal Agents; Biofilms; Drug Discovery; Drug Resistance, Fungal; Fungi; Humans; Models, Molecular; Mycoses; Small Molecule Libraries | 2017 |
2 other study(ies) available for magnolol and sirolimus
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Animals; Autophagy; Cognitive Dysfunction; Mammals; Mice; Mice, Transgenic; Neurodegenerative Diseases; Protein Serine-Threonine Kinases; Sirolimus; TOR Serine-Threonine Kinases | 2023 |